title: Concurrent cisplatin/radiation followed by adjuvant cisplatin/paclitaxel in treatment of patients with stage IB grade 3, IC and IIA endometrial carcinoma.
abstract: BACKGROUND
  Postoperative radiotherapy (RT) is the most commonly used adjuvant treatment in high risk endometrial carcinoma (HREC), it reduces the incidence of pelvic relapses but doesn't improve survival.
  
  
  OBJECTIVE
  This study was conducted to evaluate the efficacy and safety of concomitant weekly cisplatin and postoperative RT in HREC (stages IB grade 3, IC and IIA) followed by adjuvant cisplatin and weekly paclitaxel.
  
  
  METHODS
  Eighteen patients with pathologically confirmed endometrial carcinoma were enrolled in this study. All patients underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy (TAHBSO) and surgical staging. Five patients (28%), 4 patients (22%) and 9 patients (50%) presented with stages IB grade 3, IC and IIA respectively. All patients received cisplatin once weekly during the 6 weeks of RT. After the chemoradiation course, 4 additional adjuvant courses of cisplatin and paclitaxel were administered.
  
  
  RESULTS
  Between May 2000 and March 2002, a total of 18 patients with pathologically confirmed endometrial carcinoma, presented to Radiation Oncology & Nuclear Medicine Department, Ain Shams University Hospitals, were enrolled in this study. Their median age was 59 years. No severe toxicity was encountered during concomitant chemoradiation. Grade 3 hematological toxicities, leucopenia, neutropenia and anemia were recorded in one patient (5.6%) each during adjuvant chemotherapy. Two patients (11%) relapsed with distant metastases and one patient (5.6%) developed pelvic recurrence. Median time to progression was 67 months. Five year disease free survival and the 5 year overall survival were 89% (95%, CI: 74-100).
  
  
  CONCLUSIONS
  Concomitant cisplatin and postoperative RT followed by adjuvant cisplatin and weekly paclitaxel is safe and acceptable treatment in patients with HREC. This study verifies the feasibility of this treatment to potentially reduce the incidence of local and distant relapses in order to improve survival. Randomized phase III studies with large number of patients are necessary to evaluate the benefits of this approach.
authors.affiliation: The Department of Radiation Oncology, Ain Shams University.
authors.forename: Iman
authors.initials: I
authors.lastname: Foad
authors.forename: Iman
authors.initials: I
authors.lastname: Sharawy
authors.forename: Ehab
authors.initials: E
authors.lastname: Mostafa
authors.forename: Maha
authors.initials: M
authors.lastname: Margergis
authors.forename: Tarek
authors.initials: T
authors.lastname: Hussein
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000628:therapy; D009367:Neoplasm Staging; D010052:Ovariectomy; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D011879:Radiotherapy Dosage; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D002945:Cisplatin